Recent News Releases
For investor-related news, see our ASX releases here.
Nov 23, 2021
- CSL, WEHI and The University of Melbourne have secured funding to join forces and create an incubator and commercial wet lab space for biotech start-up companies - The project partners are...
Nov 22, 2021Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG
Ad hoc announcement pursuant to Art. 53 LR Sanifit Therapeutics and Inositec AG, both clinical stage biopharmaceutical companies, are developing first-in-class treatments for progressive vascular...
Nov 12, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Committee for Medicinal Products for Human Use (CHMP) recommends approval of first orally administered therapy for the treatment of ANCA-associated...
Oct 27, 2021Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft function
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Phase-III trial did not demonstrate a statistically significant difference from placebo on the primary endpoint of estimated Glomerular Filtration Rate...
Oct 27, 2021
Faster treatments for future pandemics (Brisbane) Investigating the DNA factory in our bodies that makes everything (Melbourne) MELBOURNE and BRISBANE; October 27, 2021: Two Australian scientists...
Oct 19, 2021
MELBOURNE, AU and KING OF PRUSSIA, PA; October 19/18, 2021: Two of Melbourne’s most prominent medical research and drug development organisations, WEHI and CSL, have joined forces to create a...
Oct 19, 2021Clinical Trial Milestones, Investments in aQIVc and sa-mRNA Influenza Vaccines and New Strategic Collaborations Among the Highlights from CSL R&D Day• CSL advances novel pipeline spanning six therapeutic areas, four scientific platforms and two businesses (CSL Behring and Seqirus)
MELBOURNE, AU and KING OF PRUSSIA, PA; October 19/18, 2021 – During its annual R&D investment briefing earlier today, CSL Limited (ASX:CSL; USOTC:CSLLY) highlighted progress from its novel...
Oct 14, 2021
CSL Reaffirms Commitment to Manufacture AstraZeneca COVID Vaccine into 2022 Melbourne, Australia: CSL is committed to the manufacture of approximately 50 million doses of the AstraZeneca COVID-19...
Oct 14, 2021The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) Efficacy in Children and Adolescents ≥2 to <18 Years of Age
Summit, NJ, USA 14 Oct 2021 Seqirus, a global leader in influenza prevention, and a business of CSL Limited (ASX:CSL), today announced that The New England Journal of Medicine has published...
Oct 14, 2021EU Flu Day 2021 – Seqirus joins experts’ calls to boost vaccine uptake ahead of a second influenza season during the COVID-19 pandemic
• Expert modelling points to a more severe influenza season than in previous years.1 • The lifting of restrictions to reduce COVID-19 transmission may leave vulnerable people – with reduced...